Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zindy, F.
Right arrow Articles by Roussel, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zindy, F.
Right arrow Articles by Roussel, M. F.
[Cancer Research 63, 5420-5427, September 1, 2003]
© 2003 American Association for Cancer Research


Regular Articles

Hemangiosarcomas, Medulloblastomas, and Other Tumors in Ink4c/p53-null Mice1

Frederique Zindy2, Lisa M. Nilsson2, Luc Nguyen, Cecile Meunier, Richard J. Smeyne, Jerold E. Rehg, Charles Eberhart, Charles J. Sherr and Martine F. Roussel3

Departments of Genetics and Tumor Cell Biology [F. Z., L. M. N., L. N., C. M., C. J. S., M. F. R.], Developmental Neurobiology [R. J. S.], and Pathology [J. E. R.] and Howard Hughes Medical Institute [C. J. S.], St. Jude Children’s Research Hospital, Memphis, Tennessee 38105, and Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland 21205 [C. E.]


    ABSTRACT
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Ink4 proteins inhibit the enzymatic activities of cyclin D-dependent kinases, thereby governing transcriptional programs that depend on the activities of the retinoblastoma protein and other retinoblastoma family members (p107 and p130). Mice lacking Ink4c and p53 spontaneously develop a broad spectrum of neoplasms, usually presenting with multiple tumors of different histological types and dying of cancer by 6 months of age. Whereas thymic lymphomas or pituitary tumors predominate in mice lacking p53 or Ink4c, respectively, animals lacking both genes develop many vascular tumors and also present with medulloblastomas not observed in the parental strains. Unlike p53, loss of the Arf tumor suppressor did not contribute to the appearance of vascular or cerebellar tumors. Vascular tumors ranged in severity from angiomas to hemangiosarcomas, some of which could be transplanted into immunocompromised mice. Intriguingly, loss of Ink4c but maintenance of at least one Ink4d allele was required for formation of medulloblastomas in p53-null mice. In situ hybridization revealed that, in newborn mice, Ink4c is detected in the pia mater and in an adjacent layer of rapidly dividing cells within the cerebellar external granule layer (EGL), whereas Ink4d is primarily expressed in Purkinje neurons. Because the pia mater and Purkinje cells sandwich the cerebellar EGL from which medulloblastomas are presumed to arise, Ink4 proteins might function in a cell-autonomous manner in governing neuronal cell cycle exit as well as in a non-cell-autonomous manner in controlling the production of diffusible mitogens and chemokines that influence postnatal development of the cerebellar EGL.


    INTRODUCTION
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
By antagonizing the activities of CDKs,4 expression of CKIs enforces exit from the cell division cycle and actively maintains cells in a quiescent state. Loss of function of certain CKIs during organismal development can lead to unscheduled proliferation, resulting in organomegally, defects in the execution of certain differentiation programs, and susceptibility to tumor formation later in life (1, 2, 3, 4) . CKIs belong to two distinct gene families. The Ink4 proteins (p16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4d) specifically bind to and inhibit the activity of the CDKs, CDK4 and CDK6 (1 , 4) . Ink4 polypeptides prevent phosphorylation of proteins of the Rb gene family (including Rb itself, p107, and p130), thereby maintaining them in their active, growth-inhibitory states. In turn, Rb family members suppress the transcription of E2F-responsive genes that normally drive the entry of cells into the DNA synthetic (S) phase of the cell division cycle (5, 6, 7) . Members of a second family of CKIs, the Cip/Kip proteins (p21Cip1, p27Kip1, and p57Kip2), are potent inhibitors of cyclin E- and A-dependent CDK2 and reinforce the Ink4 proteins in inhibiting S-phase entry and progression (8) . Members of both CKI families can complement one another’s functions during development, sometimes through coexpression in particular cell types, but also by coordinating the behavior of interacting cell populations in developing organs (2 , 3) .

CKI proteins are differentially expressed during mouse embryonic development and in adult tissues. Whereas Ink4a and Ink4b are not normally expressed in embryos or in young animals, Ink4c and Ink4d are ubiquitously expressed in embryos and in many tissues of adult mice, usually in nonoverlapping patterns (9) . Both Ink4c and Ink4d are expressed in many regions of the developing central nervous system; Ink4c seems to be preferentially localized to proliferating neurons as they exit the cell cycle, whereas Ink4d is detected mainly in postmitotic neurons (10) . Expression of p19Ink4d and p27Kip1 is maintained in postmitotic cells of the adult brain, including Purkinje and granule neurons in the adult cerebellum (10) . Codeletion of both genes in the mouse allows differentiated neurons in various parts of the brain to undergo inappropriate cell divisions, leading to neuronal apoptosis and, ultimately, to gross neurological dysfunction and death between P14 and P24 (11) . This suggests that p19Ink4d and p27Kip1 normally collaborate to actively maintain certain neurons in a postmitotic state. In contrast, in the organ of Corti within the inner ear, p19Ink4d alone is required for maintenance of sensory hair cells in a quiescent state, whereas p27Kip1 keeps supporting cells from dividing. Loss of Kip1 leads to the appearance of supernumerary supporting cells, whereas disruption of Ink4d induces sensory hair cells to reenter the cell cycle and die, with loss of either CKI leading to deafness (12 , 13) . Like mice lacking Kip1 (14, 15, 16) , animals lacking Ink4c exhibit organomegally (17 , 18) . Both Kip1-null and Ink4c-null mice develop pituitary adenomas (14, 15, 16, 17, 18) , whose time of onset is greatly accelerated in animals lacking both genes (17 , 19) .

Loss of Ink4d does not accelerate tumor formation in Ink4c-null mice, but males lacking these two CKIs cannot produce viable sperm and are sterile (20) . We interbred the Ink4c/Ink4d-null mice with animals lacking p53, reasoning that apoptosis in developing male germ cells might be mitigated on a p53-null background and lead to testicular tumors. Mice lacking both Ink4c and p53 were highly tumor-prone, and the frequency of germ cell tumors was not increased by codeletion of Ink4d. Instead, we detected a high incidence of vascular tumors, as well as medulloblastomas. Studies of Ink4c and Ink4d expression in the developing cerebellum indicated that Ink4c is expressed primarily in cells of the pia mater and, between P5 and P10, in rapidly dividing cells of the EGL that are presumed to give rise to medulloblastoma. In contrast, Ink4d expression is restricted to Purkinje neurons. These data suggest that Ink4 proteins may play both cell-autonomous and non-cell-autonomous roles in tumor formation.


    MATERIALS AND METHODS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Mouse Colonies.
Female mice doubly deficient for Ink4d and Ink4c (20) were crossed with p53-deficient males (Jackson Laboratory, Bar Harbor, ME) to generate mice heterozygous for all three genes. The latter were intercrossed to generate compound genotypes, which were born at the expected Mendelian frequencies. All mice were from a mixed (129SvJ x C57BL/6) genetic background. Genotyping for p53 (21) or Ink4c (18) was performed by PCR. Ink4d genotyping by PCR used the following primers: wild-type Ink4d alleles were amplified with forward primer 5'-CAAGATGCCTCCGGTACTAG-3' and reverse primer 5'-AAGCTGACCACGGAGCTATG-3'; and the Ink4d-null allele was amplified using forward primer 5'-CACGAGATTTCGATTCCACC-3', and the same reverse primer used for the wild-type allele. The animals were maintained in accordance with approved St. Jude Children’s Research Hospital guidelines and observed daily for up to 6 months of age.

Tumor and Cell Transplants.
EOMA cells [a kind gift from R. Auerbach (University of Wisconsin); Ref. 22 ] were transplanted by injection of 1 x 106 cells s.c. on each shoulder of NOD/SCID mice. Hemangiosarcomas were transplanted into NOD/SCID mice as described previously (23) . Tumor growth was monitored daily.

Histopathology, Immunohistochemistry, and in Situ RNA Hybridization.
Moribund mice were sacrificed using CO2 inhalation. Tumors and organs from each animal were systematically collected for pathology and immunohistochemical analyses. Tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin. Tissue sections of 5 µm were stained with H&E for histopathological analysis and characterized by immunohistochemistry (24) . Heat-induced epitope retrieval was performed in citrate buffer (pH 6.0) or in target retrieval solution (pH 6.2; DAKO, Carpinteria, CA) as described previously (25) . Vascular tumors were stained with antibodies to proteins that characteristically mark endothelial cells: CD31 and CD34 (PharMingen, San Diego, CA); VEGF-R2 (R&D Systems, Minneapolis, MN); and Factor 8 (DAKO). B- and T-cell lymphomas were characterized by staining with antibodies to CD3, CD45R/B220, CD138, terminal deoxynucleotidyl transferase, IgM, and {kappa} light chain as described previously (25) . Nonvascular tumors were stained with antibodies to determinants expressed on soft tissue mesenchymal and epithelial cells: desmin, muscle-specific actin, myogenin, smooth muscle actin, cytokeratin wide spectrum, and S-100 (all from DAKO); and cytokeratin AE1/AE3 (Chemicon International, Temecula, CA). Biotinylated second antibodies were from Vector Laboratories (Burlingame, CA) or Santa Cruz Biotechnology (Santa Cruz, CA). Negative controls were prepared by omitting primary antibody and substituting isotype-matched IgGs at equivalent concentrations.

For examination of brain tumors, formalin-fixed, paraffin-embedded mouse brain sections were deparaffinized, and antigen retrieval was performed for 1 min in a pressure cooker with antigen unmasking solution (Vector Laboratories). Endogenous peroxidase activity was quenched with 3% H2O2 for 5 min at room temperature. Sections were incubated for 45 min at room temperature with mouse monoclonal antibodies specific for nestin (1:300; BD PharMingen) or synaptophysin (1:100; DAKO) or with rabbit polyclonal antibodies for GFAP (1:1000; DAKO). Primary antibodies were visualized with either mouse or rabbit Vectastain Elite ABC kits (Vector Laboratories) following manufacturer’s instructions. In situ hybridizations were performed with antisense probes from Ink4d and Ink4c mouse cDNAs on sections of heads from E11.5 embryos to P5 and on sections of brain from adult mice, as described previously (10) .


    RESULTS
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Mice Lacking Ink4c and p53 Rapidly Develop a Broad Spectrum of Tumors.
Disruption of p53 in the mouse germ line primarily predisposes the animals to thymic lymphomas (~70% incidence), leading to the death of afflicted animals within 6 months of birth (21 , 26) . Other tumors arising in p53-null animals include teratomas and sarcomas of various origins, including hemangiosarcomas at a significant but relatively low incidence (8–23%, depending on genetic background; Ref. 27 ). The overall incidence of sarcomas (57% penetrance) is increased in p53+/- strains where the wild-type p53 allele is inactivated in the tumors, but the fraction of hemangiosarcomas is not correspondingly elevated (21) . Ink4c-null mice, as well as those lacking both Ink4c and Ink4d, develop pituitary intermediate lobe tumors (75%) and T-cell lymphomas (~10%) late in life, with mean latencies of 12 and 14 months, respectively (17 , 18 , 20) .

Our initial goal was to try to restore male fertility in Ink4c/Ink4d-null mice by inhibiting p53-dependent apoptosis, so we bred these animals onto a p53-null or Arf-null background. Mice lacking p53 and one or two Ink4c alleles, regardless of Ink4d status, became moribund as early as 2 months of age, and by ~30 weeks, all had succumbed to cancer (Fig. 1)Citation . In contrast, when crossed into an Arf-null background, mice lacking Ink4c did not develop any overt disease by 4 months of age, apart from incipient pituitary tumors. The survival curves (Fig. 1)Citation suggest that animals lacking p53 and only one copy of Ink4c develop tumors more slowly than mice lacking both Ink4c alleles, but these apparent differences were not statistically significant, given the sizes of the cohorts studied.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1. Tumor-free survival of mice of different genotypes. Mice were sacrificed when they became moribund. {blacksquare}, Ink4d+/+, Ink4c+/+, p53-/- (n = 19); {triangledown}, Ink4d+/+, Ink4c+/-, p53-/- (n = 23); {diamondsuit}, Ink4d+/+, Ink4c-/-, p53-/- (n = 36); {circ}, Ink4d-/-, Ink4c-/-, p53-/- (n = 27); ({perp}) Ink4d+/+, Ink4c-/-, Arf-/- (n = 62).

 
In general, by the time they became ill, animals lacking p53 and at least one Ink4c allele had spontaneously developed multiple tumors, frequently arising from completely different cell types (Table 1)Citation . Loss of one or two copies of Ink4c together with p53 did not significantly accelerate the onset of thymic lymphomas (mean latency, 16 weeks) that are associated with p53 loss alone. Animals lacking both Ink4c alleles (or, in one case, only one) developed mid-lobe pituitary adenomas, as expected (17 , 18) . Mice lacking p53 and one (~83%) or both (~88%) Ink4c alleles also developed endothelial cell hyperplasias and vascular tumors of different degrees of severity, regardless of their Ink4d status. A significant number of animals developed brain tumors, most of which were medulloblastomas. Intriguingly, although medulloblastomas appeared in animals lacking one or both Ink4c alleles, no such tumors were observed in animals that also lacked both copies of Ink4d. Therefore, retention of Ink4d appears to facilitate medulloblastoma formation in the p53/Ink4c-null setting (see below).


View this table:
[in this window]
[in a new window]
 
Table 1 Incidence of tumors in p53-null mice lacking different Ink4 alleles

 
Vascular Tumors in Mice Lacking Ink4c and p53.
Vascular tumors in p53-null animals lacking one or both Ink4c alleles arose at many different sites, including the heart, skeletal muscles, and s.c. tissues and in the omentum. In some cases, necropsy revealed the presence of multiple vascular tumors in addition to the other tumors types summarized in Table 1Citation . A gradient of pathologies was observed ranging from simple endothelial cell hyperplasia and benign angiomas to frank hemangiosarcomas (Fig. 2A)Citation . Histological staining revealed the presence of highly vascularized tissues with pleomorphic, dense nuclei and visible mitotic figures (Fig. 2B)Citation . Cells within the tumor masses expressed endothelial markers including CD31 (Fig. 2C)Citation , CD34 (Fig. 2D)Citation , VEGF-R2 (Fig. 2E)Citation , and von Willebrand factor (Factor 8; data not shown). The incidence of hemangiosarcomas was high in all p53-null mice lacking at least one Ink4c allele (Table 2)Citation .



View larger version (68K):
[in this window]
[in a new window]
 
Fig. 2. Hemangiosarcomas in p53/Ink4c-null mice. A, a representative tumor invading skeletal muscle. B, tumor histology, H&E stain. C–E, immunohistochemical staining for CD31 (C), CD34 (D), and VEGF-R2 (E). F, a primary tumor taken for transplantation with tumor histology shown in G. H, a transplanted tumor arising in a NOD/SCID mouse, with tumor histology shown in I.

 

View this table:
[in this window]
[in a new window]
 
Table 2 Incidence of hemangiosarcomas in p53-null mice lacking Ink4 alleles

 
Because many vascular tumors were aggressive, we transplanted several hemangiosarcomas from mice of different founding genotypes into immunocompromised NOD/SCID recipients. Primary tumors (Fig. 2, F and G)Citation were excised and divided, and pieces were injected s.c. into cohorts of three to six recipient animals. As a positive control, we used a transformed endothelial cell line, EOMA, which is vascular endothelial growth factor independent, can form capillaries when grown in Matrigel, and can be easily propagated by transplantation. Many of the primary tumors could be transplanted, reappearing and growing at s.c. sites of implantation within a month in at least some recipients (Fig. 2H)Citation . These transplanted tumors exhibited the same pathological characteristics as those seen in the primary tumors from Ink4c+/-/p53-/- or Ink4c-/-/p53-/- animals and were virtually indistinguishable from them (Fig. 2, H and I)Citation . These tumors can now be serially transplanted. To date, however, all attempts to propagate primary hemangiosarcomas in tissue culture have been unsuccessful, possibly because the tumors consist of multiple cell populations, of which endothelial cells represent only one component.

Medulloblastomas Develop in Mice Lacking Ink4c and p53 but Retaining Ink4d.
Unexpectedly, mice lacking p53 and Ink4c, but retaining one or two copies of Ink4d, developed brain tumors in addition to all other tumors listed in Table 1Citation . The frequency of brain tumor formation ranged from 8% to 24% in animals lacking Ink4c alleles (Table 1)Citation but dropped to 3.7% in mice also lacking both Ink4d alleles. The latter differences were significant (P < 0.02), implying that complete Ink4d loss counteracts these effects of Ink4c deletion. Moreover, whereas Ink4c loss predisposes animals to medulloblastoma formation (see below), the two brain tumors detected in animals lacking p53 and Ink4d but retaining one or both copies of Ink4c represented rare PNETs, perhaps reflecting only p53 deficiency, as described earlier by others (26) . The similar frequency of tumor formation in Ink4c heterozygotes and Ink4c-null mice could reflect inactivation of the wild-type allele or haploinsufficiency at the Ink4c locus, which has been demonstrated in other settings (28) . This has not been further studied.

Brain tumors in the Ink4c/p53-deficient animals, 15 in toto, included a majority (12) that were predominantly cerebellar (Table 3)Citation . The tumors tended to spread along the surface of the cerebellar cortex and often grew outward as exophytic masses. Inward infiltration of the tumor through the molecular layer and into the granular cell layer and cerebellar white matter was also observed in the majority of cases (Fig. 3A)Citation . In one mouse, the cerebellar tumor extended into the brain stem; in another, separate tumor foci were seen in the olfactory bulb. Cerebellar tumors exhibited closely packed, round to oval embryonal cells with scant cytoplasm (Fig. 3B)Citation that closely resembled human medulloblastomas (Fig. 3C)Citation . The tumors often contained anaplastic regions with enlarged cells, cellular wrapping, and increased mitotic activity (Fig. 3D)Citation , features commonly found in human anaplastic medulloblastoma. Tumor nodules in the brain stem (Fig. 3E)Citation and cerebral cortex (Fig. 3F)Citation were also densely cellular and contained cells with prominent nucleoli and tumor giant cells. To confirm that the cerebellar tumors were medulloblastomas and not other primary central nervous system neoplasms or metastatic lesions, such as lymphomas, sections were stained for markers of glial (GFAP; Fig. 3GCitation ) and neuronal (synaptophysin; Fig. 3HCitation ) differentiation and for the intermediate filament nestin (Fig. 3I)Citation , which is expressed in primitive neuroepithelial cells and embryonal tumors. All cerebellar tumors stained positively for each of these markers in areas with little or no normal brain tissue, confirming that they exhibited divergent neuroectodermal differentiation and were bona fide medulloblastomas.


View this table:
[in this window]
[in a new window]
 
Table 3 Incidence, location, and type of brain tumors in p53-null mice lacking Ink4 alleles

Six cohorts of mice developed brain tumors (Table 1)Citation . No animals lacking both Ink4d alleles developed medulloblastomas, but these animals died of other tumor types at the same mean age as other cohorts (Fig. 1)Citation .

 


View larger version (150K):
[in this window]
[in a new window]
 
Fig. 3. Histopathology of brain tumors. A, tumors arising in Ink4c/p53-null mice were most often centered on the cerebellar surface (arrowhead) and invaded inward through the molecular layer into the IGL (arrow; x200 magnification). B, tumors were composed of closely packed embryonal cells with little cytoplasm (x400). C, human medulloblastoma (x400). D, murine medulloblastomas often contained anaplastic regions with enlarged cells, cellular wrapping (arrow), and increased mitotic activity (arrowhead; x1000). E, brain stem lesion containing enlarged tumor cells with prominent nucleoli (x400). F, tumor nodules detected at supratentorial sites remote from the cerebellar lesion, such as a cortical lesion (asterisk) adjacent to the hippocampus (arrow; x100). Giant cells were identified in some cerebral lesions (inset). G, like human medulloblastoma (left panel), many mouse tumors showed glial differentiation as evidenced by GFAP expression (right panel, x400). H, scattered synaptophysin-positive cells were also present in the same lesions (x400). I, nestin, a marker of primitive neuroepithelial cells, was also expressed in tumor cell processes.

 
Tumors involving only the cerebral cortex or brain stem were also densely cellular and were somewhat more infiltrative than the cerebellar medulloblastomas. However, like the medulloblastomas, these extracerebellar lesions were also made up of highly atypical cells expressing GFAP, synaptophysin, and nestin. The WHO classification designates embryonal lesions with divergent differentiation arising outside the cerebellum as PNET, and we classified the murine extracerebellar tumors according to this scheme.

Examination of more than 30 cerebella from brain tumor-free animals of similar genotypes and ages (4–5 months) as the ones that developed medulloblastoma failed to reveal definitive precursor lesions. However, in several cases with smaller cerebellar lesions, the bulk of the tumor was clearly on the surface of the brain with only limited inward growth, suggesting that the tumors might arise at peripheral sites occupied by the proliferating EGL during cerebellar development. Brain stem lesions located adjacent to the fourth ventricle could have arisen from periventricular germinal matrix cells. An expanded and cytologically atypical ventricular zone subadjacent to the lateral ventricle in one mouse lacking an overt tumor could represent a precursor of supratentorial PNET. In animals with both cerebellar and cortical tumors, the cortical lesions could either have arisen independently or spread from the primary cerebellar site via the cerebral spinal fluid, as often occurs in humans.

To further assess the different contributions of Ink4c and Ink4d to tumor development, we evaluated their expression by in situ RNA hybridization in the cerebella of wild-type mice from E11.5 into adulthood (Fig. 4)Citation . At E11.5 (Fig. 4, A and K)Citation , the cerebellar anlage is a crescent-shaped structure consisting of a thick NE containing dividing neuroblasts and a DZ containing the earliest developing nuclear cells. At this time, an epithelial layer that covers the cerebellum will develop into the pial membrane (pia). Another epithelial layer, the medullary vellum (mv), will develop into the roof of the fourth ventricle. Expression of Ink4c RNA was detected in the developing pia (Fig. 4B)Citation , whereas Ink4d RNA was localized to the DZ (Fig. 4L)Citation . No expression of either gene was seen within the NE. By E13.5 (Fig. 4, C and M)Citation , the cerebellar anlage becomes a closed outpocketing of the hindbrain containing three distinct DZs. Recently born nuclear cells produced in the NE reside in DZ1 and move to their final position in DZ2, whereas early postmitotic Purkinje cells reside in DZ3. Ink4c and Ink4d were expressed in the pia (Fig. 4D)Citation and in DZ1 and DZ3 (Fig. 4N)Citation , respectively.



View larger version (166K):
[in this window]
[in a new window]
 
Fig. 4. In situ expression of Ink4c and Ink4d mRNAs in the developing cerebellum (from E11.5 to P5) and in the adult brain. The formation of the cerebellum from E11.5 through the first postnatal weeks of life is described in the text. It is thought that rapidly proliferating GCPs that make up the EGL of the developing cerebellum can sustain oncogenic insults that lead to formation of medulloblastomas. cn, cerebellar nucleus; dev skull, developing skull; dz, DZ; egl, EGL; gt, GT; mv, medullary vellum; ne, neuroepithelium; pcl, Purkinje cell layer; pcp, PCPs; pia, pia mater; igl, IGL. Scale bars: A, B, K, and L, 100 µm; C, D, M, and N, 150 µm; E, F, O, and P, 200 µm; G, H, I and R, 200 µm; I, J, S, and T, 200 µm.

 
By E15.5, cells from the posterolateral GT (Fig. 4P)Citation have migrated along the cerebellar surface to form the developing EGL, below which is a 3–4-cell-thick plate of Purkinje cells (PCPs; Fig. 4, E and PCitation ). Ink4c was expressed in the pial membrane and in ossifying chondrocytes of the developing skull (Fig. 4F)Citation , and an increased intensity of Ink4d staining marked the PCPs (Fig. 4P)Citation . Importantly, at this time, cells in the GT and within the EGL do not express Ink4 RNAs. However, during the first 2 postnatal weeks of life, granule cells rapidly proliferate, leave the EGL, and migrate to form the IGL. At P5 (Fig. 4, G and Q)Citation , the cerebellar cortex, covered by the thickened Ink4c-expressing pia (Fig. 4H)Citation , consists of four layers: the rapidly proliferating granule cells of the EGL; an underlying molecular layer; a multilaminar PCP; and the nascent IGL. At this time, Ink4c expression was detected within the proliferative zone of the EGL. Other markers of proliferating GCPs, including the Math1 transcription factor and Ki67, are also expressed in this population, whereas Kip1 expression is confined to a deeper layer of cells that have exited the cell division cycle and to Purkinje cells (data not shown). Ink4d was expressed in Purkinje cells and in deeper cerebellar nuclear cells (Fig. 4R)Citation . Hence, Ink4c, but not Ink4d, is expressed at P5 in GCPs that are presumed to give rise to medulloblastomas (29) .

In the adult cerebellum (Fig. 4, I and S)Citation , all cells formerly in the EGL have migrated to the IGL, so that a trilaminar cortex is established containing an outer molecular layer, a single layer of Purkinje cells (Fig. 4SCitation , pcl), and the IGL. High levels of Ink4c expression persisted only in the pial layer (Fig. 4J)Citation , whereas Ink4d expression was maintained in Purkinje cells and in deeper cerebellar nuclear cells (Fig. 4T)Citation .


    DISCUSSION
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Collaboration between Ink4c and p53, but not Arf.
Cohorts of mice with combined loss of Ink4c and p53, regardless of Ink4d status, exhibited a broader spectrum of tumors than those observed in parental p53-null and Ink4c-null strains. Of particular interest was the high incidence of hemangiosarcomas and the appearance of medulloblastomas, the latter not previously observed in the parental strains. Mice lacking Ink4c and p53 were so tumor-prone that necropsy of moribund animals usually revealed multiple primary tumors per animal, which frequently arose from entirely different cell types. Interestingly, no synergy was observed between Ink4c and Arf loss, at least during the relatively short postnatal period in which Ink4c/p53-null mice developed tumors and died. Despite the fact that p19Arf activates p53 in response to abnormally amplified mitogenic signals (30) , Arf is actively repressed during embryonic mouse development (31) , and its expression is muted in young healthy mice (9) . Moreover, p53 responds to a much broader spectrum of stress signal inputs than does Arf, particularly those triggered by genotoxic damage. Thus, the events that lead to the formation of vascular and brain tumors in Ink4c/p53-null mice might occur during early development when Arf is silent and result as a consequence of replicative DNA damage in the absence of appropriate p53 checkpoint control.

Vascular Tumorigenesis at High Penetrance.
Animals lacking both p53 and Ink4c presented with vascular tumors, the majority of which were invasive. Mice lacking p53 and Ink4a also develop such tumors with a high (56%) incidence (32) , and it remains unclear whether loss of Ink4c has more profound effects than Ink4a in this regard, or whether the observed frequencies simply reflect strain differences. Ink4c+/-/p53-/- mice also developed hemangiosarcomas, but analysis of loss of heterozygosity in these tumors was not possible, due to the mixture of cell types that comprise the tumors and the ambiguity of which cell type (endothelial or mesenchymal) is the actual tumor cell. However, haploinsufficiency for tumor formation was recently revealed when Ink4c+/- mice were challenged with chemical carcinogens (28) .

Primary hemangiosarcomas were serially transplantable by dividing tumors into pieces and introducing them s.c. into cohorts of immunocompromised mice. Not every animal receiving portions of the same primary tumor initially developed a secondary tumor at the injection site. Moreover, we were unable to establish tumor cell lines when we explanted primary tumors into culture. We therefore suspect that these tumors may be composed of interacting cell types that must be propagated in such a way that appropriate cell-cell interactions are maintained. In short, although the endothelial component of these tumors is prominent, there is no direct evidence that the proliferation of endothelial cells results from their oncogenic transformation, as opposed to their mitogenic stimulation by neighboring cells.

Roles of Ink4c and Ink4d in Medulloblastoma Formation.
Medulloblastomas, which are cerebellar embryonal neoplasms, do not arise in Ink4c-null or p53-null mice, but they appeared at a significant frequency in animals lacking both genes. Analysis of tumor histology, histochemistry, and patterns of invasion and metastasis revealed that these tumors shared many of the hallmarks of human anaplastic medulloblastomas. Medulloblastomas represent the most common malignant brain tumor in children and remain difficult to treat by combined surgical, chemo-, and radiotherapy (5-year survival, ~50%). Similar lesions, known as PNETs, which can arise outside of the posterior fossa, albeit rarely, have been observed infrequently in p53-null animals (26) .

During late embryogenesis, neural precursor cells migrate from a dorsal hindbrain structure, the rhombic lip, and advance along the cerebellar surface to form the EGL, which, in mice at birth, consists of only a single layer of cells. Postnatally, this population rapidly expands to generate a large pool of GCPs. Much of this expansion is regulated by diffusible factors, which, among others, include Shh released by neighboring Purkinje cells, Notch and Wnt ligands released by GCPs themselves, and the chemokine SDF-1{alpha}, which is released by pial cells on the cerebellar surface (29 , 33, 34, 35) . Once expanded, GCPs exit the EGL, migrating through the Purkinje cell layer to form the IGL and maturing into granule neurons by the third postnatal week. By the time this process is completed, the major population of neurons in the entire adult brain comes to consist of cerebellar granule cells.

Most investigators believe that medulloblastomas arise from GCPs that sustain mutations and are unable to properly differentiate (29) . Consistent with this view, about 30% of human medulloblastomas sustain mutations in the Shh signaling pathway that involve genes such as Patched (Ptc1), Smoothened (Smo), and Suppressor of Fused (SuFu), leading to constitutive activation of Gli transcription factors (29 , 33) . Shh signaling also up-regulates the c- and N-Myc genes, which are amplified in 10% of medulloblastomas and highly expressed in many more (36 , 37) . Ptc1+/- mice develop medulloblastomas (29) , and the incidence of tumors approaches 100% on a p53-null background (although, here again, loss of Arf does not accelerate disease; Ref. 38 ). Animals lacking ligase IV die in utero but are rescued on a p53-null background (39) ; these mice also develop medulloblastomas, implying that DNA damage in the absence of p53 checkpoint control can initiate such tumors (40) . p53 and Rb loss can collaborate in this setting because their targeted codeletion in the cerebellum results in medulloblastomas with full penetrance (41) . In principle, Ink4c loss might mimic the effects of Rb loss and similarly contribute.

Oligonucleotide microchip arrays performed with RNAs taken from medulloblastomas arising in mice of different genotypes (including Ptc1+/-/p53-/-, LigIV-/-/p53-/-, and Ink4c-/-/p53-/-) compared with RNA from the cerebellum of normal 5-day-old mice revealed that the medulloblastomas exhibited strikingly similar patterns of gene expression. Many tumors overexpressed Gli1, N-Myc, c-Myc, cyclin D1, and the SDF-1{alpha} receptor CXCR4 by at least 5-fold (42) . Therefore, they appeared to exhibit up-regulated Shh signaling, despite the different founding mutations that initiated tumorigenesis.

Ink4c expression was restricted to the developing postnatal EGL and otherwise was mostly confined to pial cells. We suspect that expression of p18Ink4c in GCPs acts together with p27Kip1 to regulate mitotic exit, after which only p27Kip1 expression is maintained in the postmitotic granule neurons that migrate from the EGL into the IGL. The brains of either Ink4c-null or Kip1-null mice are enlarged and contain extra neurons, but these cells seem to differentiate and migrate properly and make appropriate connections to other cerebellar neurons because no overt neurological deficits are observed in such mice (14, 15, 16, 17, 18, 19) . Although loss of Kip1 leads to increased proliferation in many parts of the brain, especially in regions of continuous proliferation such as the dentate gyrus, this is insufficient to induce brain tumors. Brain tumors have not been reported in any other mouse cohorts where Cip/Kip genes were deleted alone, in combination, or with p53. Therefore, defects in cell cycle regulation per se may not account for medulloblastoma development in Ink4c/p53-null mice.

Knoepfler and collaborators (43) recently found that Ink4c and Kip1 are highly expressed in the embryonic cerebellar primordium of mice in which N-Myc was conditionally deleted using a Nestin-Cre transgene. These mice develop a small cerebellum, presumably due to the abnormal expression of CKIs that suppress proliferation of the EGL. Hence, Ink4c and Kip1 are down-regulated by N-Myc, and this is likely necessary for proper granule cell development.

Ink4d was expressed in postmitotic Purkinje neurons, and its loss countered the development of medulloblastomas. Because these tumors are presumed to arise from GCPs, loss of Ink4c and Ink4d might affect the release of diffusible factors from pial and Purkinje cells, respectively, that sandwich the developing EGL. Because we saw no overt expansion of pial and Purkinje populations, there is no evidence that the role of the Ink4 proteins is to regulate their cell cycles. Instead, it may prove that the Ink4 proteins govern Rb family-dependent transcriptional programs that control cell-cell communication and the subsequent expansion and differentiation of GCPs. Evaluation of the levels of regulatory factors, such as Shh and SDF-1{alpha}, produced by Purkinje and pial cells from Ink4-deficient animals should improve our understanding of the processes involved.


    ACKNOWLEDGMENTS
 
We thank Patricia Jensen and Susan Magdaleno for assistance with in situ RNA hybridization; Adriana Nance, Linda Horner, Brenda McGowan, and Kellie Ann Christie for preparing mouse tissues for histopathology; Linda Sharp and Eduardo Vasquez for handling mouse colonies; Dorothy Bush for immunostaining; Guylaine Assem, Camu Pous Hornsby, Sussy Portillo, and Rema Menon for mouse genotyping; Jeremy D. Creech and Peter Houghton for tumor transplants; and Chenghong Li and Xiaoping Xiong for statistical analysis.


    FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grants CA 71907 (to M. F. R.), R25 CA23944 (to L. N.), Cancer Center Core Grant CA 21765, and by the American Lebanese Syrian Associated Charities of St. Jude Children’s Research Hospital. C. E. is the recipient of a Burroughs Wellcome Career Award in the Biomedical Sciences. C. J. S. is an Investigator of the Howard Hughes Medical Institute. Back

2 Both of these authors contributed equally to this work. Back

3 To whom requests for reprints should be addressed, at St. Jude Children’s Research Hospital, Danny Thomas Research Tower, 5006C, Mail stop 350, 332 North Lauderdale, Memphis, TN, 38105. Phone: (901) 495-3481; E-mail: martine.roussel{at}stjude.org Back

4 The abbreviations used are: CDK, cyclin-dependent kinase; CKI, CDK-inhibitory protein; Rb, retinoblastoma; P, postnatal day; E, embryonic day; EGL, external granule layer; NOD, nonobese diabetic; SCID, severe combined immunodeficient; VEGF-R2, vascular endothelial growth factor receptor 2; GFAP, glial fibrillary acidic protein; PNET, primitive neuroectodermal tumor; DZ, differentiating zone; NE, neuroepithelial zone; GT, germinal trigone; PCP, Purkinje cell precursor; IGL, internal granular layer; GCP, granule cell precursor; Shh, Sonic hedgehog. Back

Received 4/14/03. Revised 6/ 5/03. Accepted 6/18/03.


    REFERENCES
 Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.[Free Full Text]
  2. Harper J. W., Elledge S. J. Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev., 6: 56-64, 1996.[Medline]
  3. Nakayama K., Nakayama K. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development. Bioessays, 20: 1020-1029, 1998.[Medline]
  4. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta, 1602: 73-87, 2002.[Medline]
  5. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev., 12: 2245-2262, 1998.[Free Full Text]
  6. Nevins J. R. The Rb/E2F pathway and cancer. Hum. Mol. Genet., 10: 699-703, 2001.[Abstract/Free Full Text]
  7. Trimarchi J. M., Lees J. A. Sibling rivalry in the E2F family. Nat. Rev. Mol. Cell. Biol., 3: 11-20, 2002.[Medline]
  8. Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 13: 1501-1512, 1999.[Free Full Text]
  9. Zindy F., Quelle D. E., Roussel M. F., Sherr C. J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene, 15: 203-211, 1997.[Medline]
  10. Zindy F., Soares H., Herzog K-H., Morgan J., Sherr C. J., Roussel M. F. Expression of INK4 inhibitors in cyclin D-dependent kinases during mouse brain development. Cell Growth Differ., 8: 1139-1150, 1997.[Abstract]
  11. Zindy F., Cunningham J. J., Sherr C. J., Jogal S., Smeyne R. J., Roussel M. F. Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA, 96: 13462-13467, 1999.[Abstract/Free Full Text]
  12. Lowenheim H., Furness D. N., Kil J., Zinn C., Gultig K., Fero M. L., Frost D., Gummer A. W., Roberts J. M., Rubel E. W., Hackney C. M., Zenner H-P. Gene disruption of p27Kip1 allows cell proliferation in the postnatal and adult organ of Corti. Neurobiology, 96: 4084-4088, 1999.
  13. Chen P., Zindy F., Abdala C., Liu F., Li X., Roussel M. F., Segil N. Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d. Nat. Cell Biol., 5: 422-426, 2003.[Medline]
  14. Fero M. L., Rivkin M., Tasch M., Porter P., Carow C. E., Firpo E., Polyak K., Tsai L-H., Broudy V., Perlmutter R. M., Kaushansky K., Roberts J. M. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell, 85: 733-744, 1996.[Medline]
  15. Kiyokawa H., Kineman R. D., Manova-Todorova K. O., Soares V. C., Hoffman E. S., Ono M., Khanam D., Hayday A. C., Frohman L. A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell, 85: 721-732, 1996.[Medline]
  16. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. Y. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.[Medline]
  17. Franklin D. S., Godfrey V. L., Lee H., Kovalev G. I., Schoonhoven R., Chen-Kiang S., Su L., Xiong Y. CDK inhibitors p18Ink4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev., 12: 2899-2911, 1998.[Abstract/Free Full Text]
  18. Latres E., Malumbres M., Sotillo R., Martin J., Ortega S., Martin-Caballero J., Flores J. M., Cordon-Cardo C., Barbacid M. Limited overlapping roles of P15INK4b and P18INK4c cell cycle inhibitors in proliferation and tumorigenesis. EMBO J., 19: 3496-3506, 2000.[Medline]
  19. Franklin D. S., Godfrey V. L., O’Brien D. A., Deng C., Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol. Cell. Biol., 20: 6147-6158, 2000.[Abstract/Free Full Text]
  20. Zindy F., den Besten W., Chen B., Rehg J. E., Latres E., Barbacid M., Pollard J. W., Sherr C. J., Cohen P. E., Roussel M. F. Control of spermatogenesis in mice by the cyclin D-dependent kinase inhibitors p18Ink4c and p19Ink4d. Mol. Cell. Biol., 21: 3244-3255, 2001.[Abstract/Free Full Text]
  21. Jacks T., Remington L., Williams B. O., Schmitt E. M., Halachmi S., Bronson R. T., Weinberg R. A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol., 4: 1-7, 1994.[Medline]
  22. Obeso J., Weber J., Auerback R. A hemangioendothelioma-derived cell line: its use as a model for the study of endothelial cell biology. Lab. Investig., 63: 259-269, 1990.[Medline]
  23. Leggas M., Stewart C. F., Woo M. H., Fouladi M., Cheshire P. J., Peterson J. K., Friedman H. S., Billups C., Houghton P. J. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin. Cancer Res., 8: 3000-3007, 2002.[Abstract/Free Full Text]
  24. Cerilli L. A., Wick M. R. Immunohistology of soft tissue and osseous neoplasms Dabbs D. J. eds. . Diagnostic Immunohistochemistry, 59-112, Churchill Livingstone (Harcourt Health Sciences) New York 2002.
  25. Inoue K., Wren R., Rehg J. E., Adachi M., Cleveland J. L., Roussel M. F., Sherr C. J. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev., 14: 1797-1809, 2000.[Abstract/Free Full Text]
  26. Donehower L. A., Harvey M., Slagle B. L., McArthur M. J., Montgomery C. A., Jr., Butel J. S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.), 356: 215-221, 1992.[Medline]
  27. Donehower L. A., Harvey M., Vogel H., McArthur M. J., Montgomery C. A., Jr., Park S. H., Thompson T., Ford R. J., Bradley A. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol. Carcinog., 14: 16-22, 1995.[Medline]
  28. Bai F., Pei X. H., Godfrey V. L., Xiong Y. Haploinsufficiency of p18INK4c sensitizes mice to carcinogen-induced tumorigenesis. Mol. Cell. Biol., 23: 1269-1277, 2003.[Abstract/Free Full Text]
  29. Wechsler-Reya R. J., Scott M. P. The developmental biology of brain tumors. Annu. Rev. Neurosci., 24: 385-428, 2001.[Medline]
  30. Sherr C. J. The. INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell. Biol., 2: 731-737, 2001.[Medline]
  31. Jacobs J. J. L., Kieboom K., Marino S., DePinho R. A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature (Lond.), 397: 164-168, 1999.[Medline]
  32. Sharpless N. E., Alson S., Chan S., Silver D. P., Castrillon D. H., DePinho R. A. p16INK4a and p53 deficiency cooperate in tumorigenesis. Cancer Res., 62: 2761-2765, 2002.[Abstract/Free Full Text]
  33. Rubin J. B., Rowitch D. H. Medulloblastoma: a problem of developmental biology. Cancer Cell, 2: 7-8, 2002.[Medline]
  34. Klein R. S., Rubin J. B., Gibson H. D., DeHaan E. N., Alvarez-Hernandez X., Segal R. A., Luster A. D. SDF-1a induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development (Camb.), 128: 1971-1981, 2001.[Abstract/Free Full Text]
  35. Zhu Y., Yu T., Zhang X-C., Nagasawa T., Wu J. Y., Rao Y. Role of the chemokine SDF-1 as the meningeal attractant for embryonic cerebellar neurons. Nat. Neurosci., 5: 719-720, 2002.[Medline]
  36. Kenney A. M., Cole M. D., Rowitch D. H. N-myc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neurons. Development (Camb.), 130: 15-28, 2003.[Abstract/Free Full Text]
  37. Berman D. M., Karhadkar S. S., Hallahan A. R., Pritchard J. I., Eberhart C. G., Watkins D. N., Chen J. K., Cooper M. K., Taipale J., Olson J. M., Beachy P. A. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (Wash. DC), 297: 1559-1561, 2002.[Abstract/Free Full Text]
  38. Wetmore C., Eberhart D. E., Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res., 61: 513-516, 2001.[Abstract/Free Full Text]
  39. Frank K. M., Sharpless N. E., Gao Y., Sekiguchi J. M., Ferguson D. O., Zhu C., Manis J. P., Horner J., DePinho R. A., Alt F. W. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol. Cell, 5: 993-1002, 2000.[Medline]
  40. Lee Y., McKinnon P. J. DNA ligase IV suppresses medulloblastoma formation. Cancer Res., 62: 6395-6399, 2002.[Abstract/Free Full Text]
  41. Marino S., Vooijs M., van der Gulden H., Jonkers J., Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev., 14: 994-1004, 2000.[Abstract/Free Full Text]
  42. Lee Y., Miller H. L, Jensen Pl, Hernan R., Connelly M., Wetmore C., Zindy F., Roussel M., Curran T., Gilbertson R., McKinnon P. J. A molecular fingerprint for medulloblastoma. Cancer Res., 63: 5427-5436, 2003.
  43. Knoepfler P. S., Cheng P. F., Eisenman R. N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev., 16: 2699-2712, 2002.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Cancer Res.Home page
B. A. Hatton, E. H. Villavicencio, K. D. Tsuchiya, J. I. Pritchard, S. Ditzler, B. Pullar, S. Hansen, S. E. Knoblaugh, D. Lee, C. G. Eberhart, et al.
The Smo/Smo Model: Hedgehog-Induced Medulloblastoma with 90% Incidence and Leptomeningeal Spread
Cancer Res., March 15, 2008; 68(6): 1768 - 1776.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
D. Hambardzumyan, O. J. Becher, M. K. Rosenblum, P. P. Pandolfi, K. Manova-Todorova, and E. C. Holland
PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo
Genes & Dev., February 15, 2008; 22(4): 436 - 448.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Sasai, J. T. Romer, H. Kimura, D. E. Eberhart, D. S. Rice, and T. Curran
Medulloblastomas Derived from Cxcr6 Mutant Mice Respond to Treatment with a Smoothened Inhibitor
Cancer Res., April 15, 2007; 67(8): 3871 - 3877.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Zindy, T. Uziel, O. Ayrault, C. Calabrese, M. Valentine, J. E. Rehg, R. J. Gilbertson, C. J. Sherr, and M. F. Roussel
Genetic Alterations in Mouse Medulloblastomas and Generation of Tumors De novo from Primary Cerebellar Granule Neuron Precursors
Cancer Res., March 15, 2007; 67(6): 2676 - 2684.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
J. Pogoriler, K. Millen, M. Utset, and W. Du
Loss of cyclin D1 impairs cerebellar development and suppresses medulloblastoma formation
Development, October 1, 2006; 133(19): 3929 - 3937.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. Shakhova, C. Leung, E. van Montfort, A. Berns, and S. Marino
Lack of Rb and p53 Delays Cerebellar Development and Predisposes to Large Cell Anaplastic Medulloblastoma through Amplification of N-Myc and Ptch2.
Cancer Res., May 15, 2006; 66(10): 5190 - 5200.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. Mendrzyk, B. Radlwimmer, S. Joos, F. Kokocinski, A. Benner, D. E. Stange, K. Neben, H. Fiegler, N. P. Carter, G. Reifenberger, et al.
Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma
J. Clin. Oncol., December 1, 2005; 23(34): 8853 - 8862.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
T. Uziel, F. Zindy, S. Xie, Y. Lee, A. Forget, S. Magdaleno, J. E. Rehg, C. Calabrese, D. Solecki, C. G. Eberhart, et al.
The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation
Genes & Dev., November 15, 2005; 19(22): 2656 - 2667.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
T. A. Milne, C. M. Hughes, R. Lloyd, Z. Yang, O. Rozenblatt-Rosen, Y. Dou, R. W. Schnepp, C. Krankel, V. A. LiVolsi, D. Gibbs, et al.
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors
PNAS, January 18, 2005; 102(3): 749 - 754.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. R. Hallahan, J. I. Pritchard, S. Hansen, M. Benson, J. Stoeck, B. A. Hatton, T. L. Russell, R. G. Ellenbogen, I. D. Bernstein, P. A. Beachy, et al.
The SmoA1 Mouse Model Reveals That Notch Signaling Is Critical for the Growth and Survival of Sonic Hedgehog-Induced Medulloblastomas
Cancer Res., November 1, 2004; 64(21): 7794 - 7800.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. Zindy, R. T. Williams, T. A. Baudino, J. E. Rehg, S. X. Skapek, J. L. Cleveland, M. F. Roussel, and C. J. Sherr
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo
PNAS, December 23, 2003; 100(26): 15930 - 15935.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow